Flowers Foods (FLO)
(Delayed Data from NYSE)
$23.24 USD
+0.38 (1.66%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $23.24 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
B Value C Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$23.24 USD
+0.38 (1.66%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $23.24 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
B Value C Growth D Momentum B VGM
Zacks News
Flowers Foods (FLO) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Flowers Foods (FLO) delivered earnings and revenue surprises of 15.79% and 2.21%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Factors to Note as Flowers Foods (FLO) Lines Up for Q1 Earnings
by Zacks Equity Research
Flowers Foods' (FLO0 first-quarter results are likely to reflect the impacts of cost inflation, while pricing should offer some respite.
US Foods (USFD) Q1 Earnings Top Estimates
by Zacks Equity Research
US Foods (USFD) delivered earnings and revenue surprises of 2.86% and 0.04%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Aramark (ARMK) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Aramark (ARMK) delivered earnings and revenue surprises of 4.76% and 2.19%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Philip Morris (PM) Q1 Earnings & Revenues Top Estimates
by Zacks Equity Research
Philip Morris' (PM) first-quarter 2022 results reflect higher earnings and revenues, with favorable pricing variance being an upside.
The Estee Lauder Companies' (EL) Online Sales Bode Well
by Zacks Equity Research
The Estee Lauder Companies (EL) is benefiting from a strong e-commerce business. Also, the company's Skin Care portfolio has been performing well.
Pilgrim's Pride (PPC) Gains on Solid Performance, Growth Efforts
by Zacks Equity Research
Pilgrim's Pride (PPC) is benefiting from the foodservice business rebound. The company's customer-centric approach supports its unique offerings.
3 Key Factors That Make Flowers Foods (FLO) a Delectable Stock
by Zacks Equity Research
Flowers Foods (FLO) is on track with its core priorities, which include concentrating on brands, prioritizing margins and looking out for prudent mergers and acquisitions.
Procter & Gamble (PG) Tops on Q3 Earnings & Sales, Hikes View
by Zacks Equity Research
Procter & Gamble's (PG) Q3 results gain from the rising demand for cleaning products, robust sales growth and pricing gains. Management raises the fiscal 2022 view.
Archer Daniels' (ADM) Strategic Efforts & Nutrition Unit Aid
by Zacks Equity Research
Archer Daniels (ADM) effortlessly advances on its growth strategies that assure to optimize the core, drive efficiencies, innovate and expand strategically.
Archer Daniels (ADM) Expands Alternative Protein Production
by Zacks Equity Research
Archer Daniels (ADM) announces plans to invest roughly $300 million to expand its Decatur, IL, alternative protein production.
Tyson Foods (TSN) Solid Brands & Capacity-Expansion Efforts Aid
by Zacks Equity Research
Tyson Foods (TSN) is focused on higher protein production to cater to the rising demand for protein-packed food.
Post Holdings (POST) Provides Adjusted EBITDA View for FY22
by Zacks Equity Research
Post Holdings (POST) offers the adjusted EBITDA guidance for fiscal 2022, which takes into account the labor market and the input cost scenario and the latest avian influenza-related announcement.
Coty (COTY) Up More Than 10% in 6 Months: More Room for Growth?
by Zacks Equity Research
Coty (COTY) has been gaining from its six core priorities and prudent alliances. The company's solid products and brands have been aiding, while cost inflation and supply-chain woes hurt.
The J.M. Smucker (SJM) Troubled by High Costs: Pricing Aids
by Zacks Equity Research
The J.M. Smucker Company (SJM) is battling cost-related challenges and supply-chain hurdles. However, revival in the Away from Home division and pricing actions bode well.
Conagra (CAG) Q3 Earnings & Sales Top Estimates, Cost Woes Stay
by Zacks Equity Research
Conagra Brands' (CAG) Q3 fiscal 2022 results reflect lower earnings due to increased cost inflation. Management ups the organic net sales view and cuts adjusted operating margin and earnings per share guidance.
Sysco (SYY) Benefits From Recipe for Growth: Cost Woes Stay
by Zacks Equity Research
Sysco Corporation (SYY) is gaining on its Recipe for Growth plan, which involves five strategic priorities. However, high labor and transport costs pose threat to margins.
Lamb Weston (LW) Q3 Earnings Top Estimates, Sales Rise Y/Y
by Zacks Equity Research
Lamb Weston's (LW) third-quarter fiscal 2022 results reflect year-over-year sales and earnings growth on favorable price/mix. However, increased cost inflation is a concern.
Constellation Brands (STZ) Rises on Q4 Sales & Earnings Beat
by Zacks Equity Research
Constellation Brands' (STZ) Q4 results reflect continued strength in the beer business, aided by strong demand. Management issues an upbeat fiscal 2023 view.
Nu Skin (NUS) Up More Than 15% in 6 Months: Here's Why
by Zacks Equity Research
Nu Skin (NUS) is benefiting from technological advancements and strategic product programs. Management is optimistic about its Nu Vision 2025 strategy.
Kimberly-Clark (KMB) Faces High Costs, Down Over 10% in 3 Months
by Zacks Equity Research
Kimberly-Clark (KMB) is battling high input costs for the past few quarters. Soft sales in the company's Consumer Tissue segment are also a concern.
Medifast (MED) Troubled by High SG&A Costs, Gross Margin Woes
by Zacks Equity Research
Medifast (MED) has been seeing high SG&A expenses for a while now, mainly due to higher OPTAVIA commission costs. The company's gross margin has also been under pressure.
Church & Dwight (CHD) Up More Than 20% in 6 Months: Here's Why
by Zacks Equity Research
Church & Dwight (CHD) has been gaining on robust consumption and demand trends. The company's innovation and prudent acquisitions, together with pricing actions, have been aiding amid high costs.
Philip Morris (PM) Benefits From Pricing Power & Focus on RRPs
by Zacks Equity Research
Philip Morris (PM) has been benefiting from its strong pricing power. Additionally, its focus on moving toward a majority smoke-free company bodes well.
Newell Brands (NWL) Divests Home & Security Unit to Resideo
by Zacks Equity Research
Newell Brands (NWL) completes the sale of the CH&S unit to Resideo to focus on core categories. The move will help reduce debt and fund share repurchases.